141645-23-0

Basic information

• Product Name: (2-Butyl-5-nitro-3-benzofuranyl)[4-[3-(dibutylamino)propoxy]phenyl]methanone
• Synonyms: (2-Butyl-5-nitro-3-benzofuranyl)[4-[3-(dibutylamino)propoxy]phenyl]methanone;(2-butyl-5-nitrobenzofuran-3-yl)(4-(3-(dibutylaMino)propoxy)phenyl)Methanone;4-[(2-butyl-6-nitro-1-benzofuran-3-yl)carbonyl]phenol;2-butyl-5-nitro-3-benzofuranyl)[4-[3-(dibutylaMino)propoxy]phenyl]-;Methanone, (2-butyl-5-nitro-3-benzofuranyl)[4-[3-(dibutylaMino)propoxy]phenyl]-;2-Butyl-3-[4-(2-Dibutylaminopropoxy)benzoyl]-5-Nitrobenzofuran;Dronedarone Impurity D;(2-butyl-5-nitro-1-benzofuran-3-yl)-[4-[3-(dibutylamino)propoxy]phenyl]methanone
• CAS NO: 141645-23-0
• Molecular Formula: C₃₀H₄₀N₂O₅
• Molecular Weight: 508.65
• EINECS: 1806241-263-5
• Product Categories: API
• Mol File: 141645-23-0.mol
• Article Data: 16

Chemical Properties

• Boiling Point: 638.148 °C at 760 mmHg
• Flash Point: 339.74 °C
• Appearance: Off-white crystalline
• Density: 1.109
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.56
• PKA: 9.43±0.50(Predicted)
• CAS DataBase Reference: (2-Butyl-5-nitro-3-benzofuranyl)[4-[3-(dibutylamino)propoxy]phenyl]methanone(CAS DataBase Reference)
• NIST Chemistry Reference: (2-Butyl-5-nitro-3-benzofuranyl)[4-[3-(dibutylamino)propoxy]phenyl]methanone(141645-23-0)
• EPA Substance Registry System: (2-Butyl-5-nitro-3-benzofuranyl)[4-[3-(dibutylamino)propoxy]phenyl]methanone(141645-23-0)

Safety Data

• Hazardous Substances Data: 141645-23-0(Hazardous Substances Data)

Usage

General Description

The chemical compound "(2-Butyl-5-nitro-3-benzofuranyl)[4-[3-(dibutylamino)propoxy]phenyl]methanone" is a complex molecule with a long chain structure. It consists of a benzofuranyl ring with a butyl and nitro group attached, as well as a phenylmethanone group connected to a dibutylamino propoxy chain. (2-Butyl-5-nitro-3-benzofuranyl)[4-[3-(dibutylamino)propoxy]phenyl]methanone is used in pharmaceutical research and has potential applications in drug development, particularly in the areas of cardiovascular and central nervous system disorders. Its specific properties and potential uses would require further research and testing.

InChI:InChI=1/C30H40N2O5/c1-4-7-11-28-29(26-22-24(32(34)35)14-17-27(26)37-28)30(33)23-12-15-25(16-13-23)36-21-10-20-31(18-8-5-2)19-9-6-3/h12-17,22H,4-11,18-21H2,1-3H3

Upstream product

• 141645-16-1 2-n-butyl-3-(4-hydroxybenzoyl)-5-nitrobenzofuran 
• 36421-15-5 dibutyl-(3-chloro-propyl)-amine 
• 114980-27-7 4-<3-(dibutylamino)propoxy>benzaldehyde 
• 638-29-9 n-valeryl chloride 
• 772-33-8 Koshlands reagent I 
• 20120-23-4 3-dibutylaminopropionic acid ethyl ester 
• 111-92-2 dibutylamine 
• 540-38-5 p-Iodophenol 
• 89487-91-2 2-iodo-4-nitrophenol 
• 2050-51-3 3-dibutylaminopropanol 
• 33527-94-5 4-acetoxyiodobenzene 
• 1636167-45-7 2-(hex-1-yn-1-yl)-4-nitrophenyl acetate 
• 504421-91-4 2-iodo-4-nitrophenyl acetate 
• 1356411-44-3 C₃₀H₄₃N₃O₅ 

Downstream Products

• 141626-36-0 dronedarone 
• 141626-57-5 N-(2-butyl-3-(4-(3-(dibutylamino)propoxy)-benzoyl)benzofuran-5-yl)-N-(methylsulfonyl)methanesulfonamide 
• 141625-93-6 dronedarone hydrochloride 
• 500791-70-8 5-amino-2-n-butyl-3-[4-(3-di-n-butylamino propoxy)benzoyl]benzofuran bisoxalate 
• 1278585-69-5 N-(2-butyl-3-(4-(3-(dibutylamino)propoxy)benzoyl)benzofuran-5-yl)acetamide 
• 1354567-98-8 2-n-butyl-3-{4-[3-(di-n-butylamino)propoxy]benzoyl}-5-aminobenzofuran hydrochloride 
• 1354567-97-7 N-[2-butyl-3-[4-(3-(di-n-butylamino)propoxy)benzoyl]-5-benzofuranyl]methanesulfonamide hydrobromide 
• 141644-91-9 (5-amino-2-butyl-benzofuran-3-yl)-[4-(3-dibutylamino-propoxy)-phenyl]-methanone 

Relevant articles and documents

Concise total synthesis of antiarrhythmic drug dronedarone via a conjugate addition followed intramolecular heck cyclization

A concise, scalable, and an efficient total synthesis for dronedarone (2) was described using conjugate addition followed by intramolecular Heck cyclization. The other key reaction includes selective reduction of nitro functionality and addition of lithiated terminal alkyne to the aldehyde. The overall yield of this approach is 44% in six steps.

Benzofuran compound and application thereof

The invention provides a benzofuran compound as shown in a formula (I) or pharmaceutically acceptable salt thereof, and application thereof. The compound can selectively inhibit activation of NLRP3 inflammasomes and inhibit maturation and secretion of inflammation activation signal molecules Caspase-1 and P20 and inflammatory cytokines IL-1beta, has a good prevention and treatment effect on NLRP3 inflammasome related diseases, and particularly has a remarkable prevention and treatment effect on peritonitis and gouty arthritis. Therefore, the compound can be used for preparing drugs for treating NLRP3 inflammasome-related diseases, such as anti-inflammatory drugs or auxiliary anti-inflammatory drugs.

Identification and characterization of potential impurities of dronedarone hydrochloride

Six potential process related impurities were detected during the impurity profile study of an antiarrhythmic drug substance, Dronedarone (1). Simple high performance liquid chromatography and liquid chromatography-mass spectrometry methods were used for the detection of these process impurities. Based on the synthesis and spectral data (MS, IR, 1H NMR, 13C NMR, and DEPT), the structures of these impurities were characterized a s 5-amino-3-[4-(3-di-n-butylaminopropoxy)benzoyl]-2-n-butylbenzofuran (impurity I); N-(2-butyl-3-(4-(3-(dibutylamino)propoxy)-benzoyl)benzofuran-5-yl)-N- (methylsulfonyl)-methanesulfonamide (impurity II); N-(2-butyl-3-(4-(3- (dibutylamino)propoxy)benzoyl)benzofuran-5-yl)-1-chloromethanesulfonamide (impurity III); N-{2-propyl-3-[4-(3-dibutylaminopropoxy)benzoyl]benzofuran-5-yl} - methanesulfonamide (impurity IV); N-(2-butyl-3-(4-(3-(dibutylamino)propoxy) benzoyl)benzofuran-5-yl)-formamide (impurity V); and (2-butyl-5-((3- (dibutylamino)propyl)amino)benzofuran-3-yl)(4-(3- (dibutylamino)propoxy)phenyl) methanone (impurity VI). The synthesis and characterization of these impurities are discussed in detail.